What is the history of Bartter's Syndrome?

Bartter's syndrome was first identified in 1962 by Dr. Frederic Bartter, who described a specific pattern of salt wasting, low potassium, and normal-to-low blood pressure in patients. Since then, our understanding of Bartter's syndrome has shifted from a clinical observation of symptoms to a precise molecular diagnosis involving specific ion channel mutations in the kidney.

How was Bartter's syndrome first discovered?

The history of Bartter's syndrome began in 1962 when Dr. Frederic Bartter and his colleagues at the National Institutes of Health published a landmark paper in The American Journal of Medicine. They described two patients with hypokalemic alkalosis, hyperaldosteronism, and resistance to the pressor effects of angiotensin II. Initially, it was believed that the syndrome was primarily a disorder of the adrenal glands, but subsequent clinical investigations corrected this, proving the pathology resided within the thick ascending limb of the loop of Henle in the kidneys.

How has our understanding of the genetics of Bartter's syndrome evolved?

The most significant leap in managing Bartter's syndrome occurred in the 1990s and early 2000s, when researchers identified the specific genetic mutations responsible for the disease. We now know that Bartter's syndrome is caused by defects in the proteins that transport salt in the kidneys, specifically the NKCC2 transporter, the ROMK channel, and the ClC-Kb chloride channel. This discovery allowed clinicians to classify the condition into distinct types (Type I through Type V), providing a much clearer picture of how Bartter's syndrome progresses in different individuals.

What are the major milestones in the treatment of Bartter's syndrome?

Treatment for Bartter's syndrome has evolved from trial-and-error symptom management to targeted physiological support. Key milestones include:

• The introduction of prostaglandin inhibitors (like indomethacin) in the 1970s to reduce salt wasting.


• The use of potassium-sparing diuretics to manage electrolyte imbalances.


• The implementation of aggressive oral salt and potassium supplementation protocols.


• The rise of patient advocacy groups, such as the 61 members currently sharing their experiences on DiseaseMaps.org, which has helped standardize care protocols.

Next steps

• Consult a pediatric or adult nephrologist to review your specific genetic subtype of Bartter's syndrome.


• Connect with the community at DiseaseMaps.org to share management strategies with others living with the condition.


• Speak with a genetic counselor to understand the inheritance patterns relevant to your family.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Bartter Syndrome.


• Orphanet: Bartter Syndrome (ORPHA:120).


• OMIM (Online Mendelian Inheritance in Man): Bartter Syndrome entries.


• The American Journal of Medicine (1962): Original description by Bartter et al.